EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices

Kathleen Nicholls iD, Charles Denaro iD, Michel Tchan iD, Carolyn Ellaway iD, Drago Bratkovic iD, Sheridan Campbell, Megan Fookes, Mark Thomas iD

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Kathleen Nicholls und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Fabry Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amicus Therapeutics, Sanofi Australia Pty Ltd, Takeda Pharmaceuticals Australia Pty Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disease‐specific therapy aims to improve symptoms, stabilise current disease and delay progression in patients with Fabry disease. In Australia, treatment access is subject to eligibility criteria initially established in 2004. Patients and their clinicians question why these criteria have remained unchanged despite significant progress in disease understanding.

Aims

Appraise the clinical quality of the Australian treatment access criteria.

Methods

The Fabry Australia Medical Advisory Committee ( N = 6) used the Appraisal of Guidelines for REsearch and Evaluation Global Rating Scale (AGREE II GRS) to assess the clinical quality of the current treatment eligibility criteria. They reviewed the literature, developed 17 clinical statements to help guide reforms of the eligibility criteria and achieved consensus (achievement of ≥75% agreement in the range 5–7 on a 7‐point Likert scale) through anonymous voting. The findings were applied to develop proposals for revised classification and treatment initiation criteria.

Results

The current treatment eligibility criteria underperformed on the AGREE II GRS. They are pragmatic but out‐of‐step with contemporary data. Consensus was achieved on all 17 proposed clinical statements. There was strong agreement to differentiate classical male Fabry patients to facilitate timelier access to Fabry‐specific treatment. There was also agreement on the value of adopting relevant organ involvement criteria in classical female patients and patients with non‐classical disease.

Conclusions

Australian access criteria are misaligned with current clinical evidence. The clinical statements and proposed classification and initiation criteria should prompt discussions to support more equitable access to treatment and better align Australian practice with contemporary evidence and international guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry DiseaseHumansAustraliaMaleFemalePractice Guidelines as TopicPatient SelectionEligibility DeterminationEnzyme Replacement TherapyConsensus

Stichwörter der Autor:innen

Fabry diseaseaccessclassificationenzyme replacement therapyhealthcare qualitymigalastat

Autor:innen und Institutionen

  • Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Academy of Medicine, University of Queensland, Brisbane, Queensland, Australia.
  • Department of Genetic Medicine, Westmead Hospital, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Kathleen Nicholls, Charles Denaro, Michel Tchan, Carolyn Ellaway, Drago Bratkovic, Mark Thomas

Förderung

  • Amicus Therapeutics
  • Sanofi Australia Pty Ltd
  • Takeda Pharmaceuticals Australia Pty Ltd

Zitieren

APA

Nicholls, K., Denaro, C., Tchan, M., Ellaway, C., Bratkovic, D., Campbell, S., Fookes, M., & Thomas, M. (2024). Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices. Internal Medicine Journal. https://doi.org/10.1111/imj.16327

Vancouver

Nicholls K, Denaro C, Tchan M, Ellaway C, Bratkovic D, Campbell S, et al. Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices. Internal Medicine Journal. 2024. doi:10.1111/imj.16327

BibTeX
@article{Nicholls2024,
  author = {Nicholls, Kathleen and Denaro, Charles and Tchan, Michel and Ellaway, Carolyn and Bratkovic, Drago and Campbell, Sheridan and Fookes, Megan and Thomas, Mark},
  title = {Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16327}
}
Kostenlos starten →